SCHEMBL25546341

SCHEMBL25546341

CC(C)Cc1sc(Cl)nc1-c1ccc(-c2ccccc2)s1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 7/20 0.47
CYP2E1 P05181 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2A6 P11509 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2B6 P20813 1/20 0.38
CYP2C19 P33261 1/20 0.38
DHODH Q02127 1/20 0.37
ALDH1A1 P00352 2/20 0.35
ACACA Q13085 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD17B1 P14061 1/20 0.35
HSD17B2 P37059 1/20 0.35
GAA P10253 1/20 0.34
HTT P42858 1/20 0.34
MAPT P10636 1/20 0.34
LMNA P02545 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25546343 0.84 FBP1 (0.50) FBP1ALDH1A1GAAMAPT
SCHEMBL25558497 0.83 FBP1 (0.40) FBP1CYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL25546346 0.78 FBP1 (0.48) FBP1CYP3A4CYP2C9HSD17B1HSD17B2
SCHEMBL25546361 0.78 FBP1 (0.43) FBP1NPSR1HSD17B1HSD17B2MAPT
SCHEMBL25546334 0.77 FBP1 (0.44) FBP1ALDH1A1MAPT
SCHEMBL25546335 0.77 FBP1 (0.50) FBP1ALDH1A1HTTMAPTLMNA
SCHEMBL25545933 0.76 TDP1 (0.44) FBP1ALDH1A1MAPTLMNA
SCHEMBL25546359 0.76 PDE4B (0.44) FBP1CYP3A4ALDH1A1NPSR1HTT
SCHEMBL25546032 0.74 KMT2A (0.47) FBP1ALDH1A1GAAMAPT
SCHEMBL13749525 0.73 CYP2A6 (0.58) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 FBP1 735/4885CYP2E1 4747/4885CYP3A4 4553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.